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Abstract
The objective of this retrospective 
study was to determine the frequency 
of Bipolar Disorder in children and 
adolescents referred to the Child 
Guidance Clinic (CGC), St. Luke’s 
Hospital, Malta, over a year. Diagnostic 
criteria were analyzed and compared to 
current literature.
Of 141 children, none were 
diagnosed with Bipolar Disorder. 
Further awareness of clinicians is 
advised, to identify Bipolar Disorder, 
thus limiting its long term morbidity and 
mortality.
   
Introduction
Pediatric bipolar disorder (BD) is a 
disorder of affective regulation; it is a 
serious mental illness with significant 
morbidity and mortality. BD is a chronic 
relapsing remitting mental disorder, 
which has a profound impact on 
morbidity and mortality.1 BD is ranked 
7th of the world-wide causes of non-
fatal disease burden.2
Most studies indicate that the onset 
of BD is frequently between ages 15-30 
years. Recently it has been reported 
that BD starts before the age of 10, 
though this is rare, it does occur.3 
The prevalence of BD is estimated at 
0.1 to 2% among adolescents.4 The 
rate of bipolar affective disorder 1 
(episodes of mania and depression) and 
bipolar affective disorder 2 (episodes 
of hypomania and depression), 
in adolescents is around 0.99% 
whereas using the wider BD spectrum 
classification (and BD NOS), studies 
report prevalence rates of up to 3%.5 
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Bipolar symptoms in young children 
mimic those in adulthood but with 
minor differences.6 These children most 
commonly present with symptoms such 
as irritability, depression, impulsivity, out-
of-control behavior, delinquent behavior, 
inappropriately happy mood, constantly 
on the move, lack of judgment and 
inflated self-esteem, delusions of 
grandeur, rapid and pressured speech, 
flight of ideas, suicidal ideation and 
behavior.7 The symptoms that were more 
prevalent in preschool children include 
irritability / dyscontrol, temper tantrums, 
poor frustration tolerance, impulsivity, 
increased aggression, decreased 
attention span, and hyperactivity.8 
Symptoms similar to adult presentations 
of depression, mania and psychosis 
were more prevalent in children with a 
bipolar diagnosis at a later age (7-12 
years).8 Patients with childhood-onset 
bipolar disorder (before 12 years of 
age) were more frequently males and 
had a more frequent co-morbidity with 
attention deficit hyperactivity disorder 
(ADHD) and oppositional defiant disorder 
(ODD) when compared to adolescent-
onset bipolar disorder.9  Patients with 
BD-NOS had an earlier age at onset and 
had frequent co-morbidities such as 
ADHD and ODD. These follow a chronic 
rather than an episodic course.10
Longitudinal studies suggest that 
pre-pubertal BD may be more difficult to 
treat than later onset BD.11  
Evidence suggests BD is often co-
morbid to ADHD, conduct disorder, 
ODD, anxiety disorders, including 
obsessive-compulsive disorder and 
generalized anxiety disorders, substance 
and alcohol abuse and personality 
disorders.11,12
Effective pharmacotherapy and 
management are critical in order 
to minimize relapses and long term 
disability, morbidity and mortality.12 
Delays in initiation of mood stabilizers, 
confers an elevated risk for suicidal 
behavior, poor social adjustment 
and more hospitalizations. Greater 
surveillance screening for bipolar illness 
may help to diminish these adverse 
outcomes.4  
The objective of this study was 
to determine the frequency of BD in 
children and adolescents referred to 
the Child Guidance Clinic (CGC) St 
Luke’s Hospital Malta, over a period of a 
year. The frequency of bipolar affective 
disorder locally was compared to that 
reported in the literature. Diagnostic 
criteria used in Malta, were also 
compared to those used in other centers 
abroad. 
Method
This retrospective study included all 
children referred to the Child Guidance 
Clinic (CGC) at St. Luke’s Hospital Malta, 
over a year from January to December 
2007. Inclusion criteria were: first visit 
to CGC, and patient ages from 8 to16 
years (both ages included). Exclusion 
criteria were a working diagnosis of 
autism spectrum disorders or mental 
retardation. Children attending Child 
Guidance Clinics in Gozo were not 
included in the study. Children reviewed 
in the private sector were not included 
in this study as data was not readily 
available, although the authors did speak 
to the relevant consultant psychiatrists 
and confirmed that no diagnosis of 
BD was made. The authors are also 
confident that if a diagnosis of BD 1 was 
made then admission to hospital for  
management of the patient would have 
been required and therefore he would 
have been referred through the public 
service route and then picked up as one 
of the cases at CGC.
Approval to carry out the study was 
obtained from the head of psychiatry at 
Mount Carmel Hospital. This study was 
also registered and approved by the 
merit award scheme. Data was collected 
Of 141 children, none were diagnosed 
with Bipolar Disorder. Further awareness 
of clinicians is advised, to identify Bipolar Disorder, 
thus limiting its long term morbidity and mortality
9
restrospectively through the case notes 
and recorded in an anonymous way, the 
information collected did not influence 
the management outcome the young 
person received at CGC.
Data collection was carried out six 
months after the end of the study period 
that was, May to June 2008. Case 
notes were reviewed, and the working 
diagnosis made by the multidisciplinary 
team at the CGC, in accordance to the 
multi-axial system used for children 
and adolescents, in the International 
classification of mental and behavioral 
disorders (WHO 1994), was recorded. 
This classification is divided in six 
axes describing: psychiatric disorder, 
delays in psychological development, 
intellectual level, medical conditions, 
psychosocial adversity and adaptive 
functioning. The most recently allocated 
working diagnosis was the one we 
recorded. Special note was taken 
to pick up any reference or formal 
diagnosis of BD in the case notes. Also 
response to treatment was recorded 
in accordance with the last entry in 
the file when reviewed by a member of 
Diagnosis Discharged Improved One Review Not improved Grand Total
Hyperkinetic disorder 4 10 25 7 46
Adjustment disorder 2 4 10 3 19
Conduct disorder 0 4 13 1 18
Anxiety disorder 0 4 8 1 13
OCD 0 2 7 2 11
Depressive disorder 0 3 2 0 5
Emotional disorders 2 2 0 1 5
Somatoform Disorder 1 2 1 0 4
Eating disorder 0 0 1 2 3
Speech and language disorder 0 0 3 0 3
Tic disorder 1 1 0 1 3
Mixed disorder conduct & emotion 0 0 2 0 2
Other behavioural and emotional disorders 0 2 0 0 2
Phobia 0 0 2 0 2
Drug abuse 1 0 0 0 1
Schizotypal disorder 0 0 1 0 1
Sexual maturation disorder 1 0 0 0 1
Social functioning disorders 0 1 0 0 1
Substance abuse 0 1 0 0 1
Total 12 36 75 18 141
Table 1: All the children referred to Child Guidance Clinic during 2007. The working diagnosis and their outcome are outlined
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the multidisciplinary team. Treatment 
resistance by the children and 
adolescence was recorded. 
Data was inputted in Microsoft 
Excel 2007 and descriptive percentages 
were tabulated.
Results
Of the 146 case files reviewed, 
141 (96.6%) children met the inclusion 
criteria. The sample consisted of 84 
males (60%) and 57 females (40%) with 
a mean age of 10.9 (±2.2).  
The distribution by diagnosis of 
the 141 children referred to CGC 
is: 46 (32.6%) were diagnosed with 
hyperkinetic disorder, 19 cases (13.5%) 
with adjustment disorder, 18 (12.8%) 
with conduct disorder, 13 (9.2%) with 
anxiety disorders and 11 (7.8%) with 
obsessive-compulsive disorder. Refer 
to Table 1 for further details on ICD-10 
diagnosis of sample. No diagnosis (0%) 
of BD was made for the 141 children 
included in the study. 
75 (53.2%) of the cohort were 
reviewed only once by the CGC 
multidisciplinary team; a working 
diagnosis and management plan was 
made but there was no-follow up during 
the study period and thus outcome 
could not be clearly established.12 
(8.5%) of all referred patients did not 
require follow-up and were discharged 
by the firm consultant due to behavioral 
presentation being in-keeping with a 
normal child development and/or the 
severity of the disorder not meeting 
criteria for specialist service and/or 
discharged at requested by the legal 
guardian. 
54 (38.3%) children had attended 
follow-ups. 36 (66.7%) of these children 
improved with the management 
plan given. Best responders were 
those diagnosed with generalized 
anxiety disorder, depressive disorder, 
somatoform disorders, and other 
behavioral and emotional disorders. 
18 (33.3%) children did not respond 
to the treatment plan, these included 
youngsters with eating disorders, tic 
disorders and obsessive-compulsive 
disorders. From our results, it was 
noticed that those children diagnosed 
with ADHD (hyperkinetic disorder) 
10
N= (%) N= (%)
Hyperkinetic disorder 10 (58.8) 7 (41.2) 100%
Conduct disorder 4 (80.0) 1 (20.0) 100%
Adjustment disorders 4 (57.1) 3 (42.9) 100%
Anxiety disorder 4 (80.0.) 1 (20.0) 100%
OCD 2 (50.0) 2 (50.0) 100%
Other behavioral and emotional 
disorders
2 (100.0) 0 - 100%
Depressive disorder 3 (100.0) 0 - 100%
Social functioning disorders 1 (100.0) 0 - 100%
Somatoform disorders 2 (100.0) 0 - 100%
Emotional disorder 2 (66.7) 1 (33.3) 100%
Tic disorder 1 (50.0) 1 (50.0) 100%
Substance abuse 1 (100.0) 0 - 100%
Eating disorders 0 - 2 (100.0) 100%
Total 36 (66.7) 18 (33.3) 100%
Table 2:  Illustration of the distribution of children, their diagnosis, and the percentage improvement over 2007
Improved No improvementDiagnosis
did fairly well, as 58.8% responded to 
the treatment given at CGC. Table 2 
illustrates the above. 
 
Limitations
The results may be limited by the 
following, (a) use of retrospective 
design; (b) small sample size i.e. over 
half of the cohort were reviewed only 
once at CGC, during the study period, 
thus improvement could not be really 
assessed; (c) ages of the children 
considered were 8-16 years; (d) children 
followed up by psychiatrists in the 
community could not be included; (e) 
children followed up at CGC in Gozo 
were not included. The authors did ask 
consultant psychiatrists working with 
children, whether they had reviewed 
anyone with BD in Gozo over that year, 
however their reply was negative. The 
authors are convinced that due to the 
nature of severity of disorder any child 
diagnosed with BD 1 would require 
hospital in-patient treatment and would 
have come to the attention of the 
national health service.
Discussion
 In comparison, the frequency of 
children and adolescents diagnosed 
with BD in Malta is significantly lower 
than that reported in the literature. 
Reasons for this could be lack of 
specific awareness in recognizing and 
diagnosing pediatric bipolar disorder 
locally, or due to the diagnostic criteria 
used. In Child Guidance Clinic, the 
multi-axial version of ICD-10, is used 
rather than the DSM IV criteria, which 
is more quoted in studies. 4,13,14 In 
the DSM IV diagnosis of BD can be 
assigned after one manic episode 
alone, while in ICD-10 the diagnosis 
is only assigned after the presentation 
of the second affective episode, one 
of which is a mixed or manic episode. 
Thus this could lead to a relative 
delayed diagnosis of BD.  
Standardized diagnostic 
assessment tools include: (a) WASH-
U-KSADS (semi-structured interview 
that yields a DSM-IV diagnosis). The 
WASH-U-KSADS has a provision for 
documenting the onset and offset of 
rapid mood swings. Inter rater reliability 
was 100% reported. (b) Child Mania 
Rating Scale Parent Version (CMRS-P) 
completed by parents, and the Young 
Mania Rating Scale (YMRS) completed 
by the clinician. The scale measures 
manic symptoms only14. (c) (KSADS-
MRS) which is a semi-structured 
interview, completed by the clinician 
after interview with the parents and 
youths sequentially. (d) The Mini 
International Neuropsychiatry Interview-
Kid (MINI-KID) is a structured interview 
that elicits co-morbid diagnoses 
in children. This has been used to 
differentiate BPD from ADHD.12 
Another finding from this study was 
that 18 (33.3%) children being treated 
the at Child Guidance Clinic did not 
improve on the treatment prescribed. 
7 of these youngsters were cases 
diagnosed with ADHD. The use of a 
more specific  diagnostic tool would 
help elucidate early clinical diagnosis 
of BD, thus excluding the possibility 
of mis-diagnosis. Studies indicate that 
children with BD alone or with other 
co-morbid illnesses are amongst the 
poorest responders to treatment.15 
Research shows that early and the 
correct psychopharmacology is critical 
to minimize the risk of morbidity and 
mortality associated with BD. This 
mental disorder carries a high risk of 
substance misuse and risk of suicide 
hence is a public health concern.4,16
The rapid increase in frequency 
reported for pediatric BD highlights a 
need for further longitudinal studies 
following up this cohort of non-
responders so as to identify reliable 
clinical and epidemiological data of BD17 
in clinical practice in Malta.   
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